NOVAFED
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOVAFED is an oral extended-release capsule small molecule approved in 1975 by Sanofi. The mechanism of action and indication are not publicly specified in available data. This product represents a legacy therapeutic from the mid-1970s era of pharmaceutical development.
LOE Approaching
Product is in late-stage maturity with modest competitive pressure (30/100), signaling a consolidation or wind-down phase for commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NOVAFED has zero linked job openings, indicating minimal hiring on this product line. Working on NOVAFED offers limited career acceleration; consider it a consolidation or maintenance role best suited for experienced professionals managing the transition to generic competition.
Brand ManagerField Sales Representative
Worked on NOVAFED at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.